Product Information
SAXAGLIPTIN HCL 2.5 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.1445 per EA under NDC 00378470593. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Jul 31, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378470593
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SAXAGLIPTIN HYDROCHLORIDE DIHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA205980FDA Approved
7/31/2023
TE Code
AB
On Market Since
8/4/2023
Pharmacological Classes
Price Statistics
The NADAC for SAXAGLIPTIN HCL 2.5 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 81.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.1445 per EA |
|---|---|
| All-time high | $6.0820 (May 15, 2024) |
| All-time low | $1.1267 (Jul 22, 2026) |
| 52-week high | $3.6026 |
| 52-week low | $1.1267 |
| Median price | $4.1879 |
| Average price | $3.5383 |
| Largest weekly change | -19.9% (Oct 22, 2025) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
saxagliptin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dipeptidyl Peptidase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SAXAGLIPTIN HCL 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SAXAGLIPTIN HCL 2.5 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $1.1445 per EA (NDC 00378470593), effective Sep 30, 2026.
How has the price of SAXAGLIPTIN HCL 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for SAXAGLIPTIN HCL 2.5 MG TABLET has declined 81.2%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for SAXAGLIPTIN HCL 2.5 MG TABLET?
Since Apr 17, 2024, the NADAC for SAXAGLIPTIN HCL 2.5 MG TABLET has ranged from a low of $1.1267 (Jul 22, 2026) to a high of $6.0820 (May 15, 2024), with a median of $4.1879 per EA.
Are there cheaper alternatives to SAXAGLIPTIN HCL 2.5 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as SAXAGLIPTIN HCL 2.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures SAXAGLIPTIN HCL 2.5 MG TABLET?
SAXAGLIPTIN HCL 2.5 MG TABLET (NDC 00378470593) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.